Characteristics of Selected Studies: Semaglutide and NAION Risk Meta-Analysis

A systematic review and meta-analysis of observational studies evaluating the association between semaglutide use and nonarteritic anterior ischemic optic neuropathy (NAION) risk in patients with type 2 diabetes. The dataset includes pooled hazard ratios and confidence intervals from studies published between January 2023 and November 2025. It was authored by Jędrzej Chrzanowski and published on figshare in May 2026.

Use Cases

• Assessing relative risk of NAION based on hazard ratios and confidence intervals from the meta-analysis
• Evaluating absolute risk of adverse events based on the reported incidence rate of 0.014%
• Comparing drug safety profiles based on comparisons with other glucose-lowering regimens
• Supporting clinical decision-making based on the evidence synthesis linking semaglutide to NAION risk

Strengths

• Includes pooled hazard ratios and confidence intervals from a meta-analysis of five observational studies
• Provides absolute risk figures (0.014%) and estimated annual incidence (1 case per 7,000 patients)
• Results are contextualized within other meta-analyses, systematic reviews, and regulatory communications

Limitations

• Description metadata is limited; actual data quality requires manual inspection after download
• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis of observational studies from PubMed, Scopus, and Web of Science.

Time Range

Studies published from January 2023 to November 2025.

Freshness

Last updated 2026-05-21 17:38:42; freshness should be verified